FRDA iPSCs |
- Generation of FRDA GAA instability model |
[38] |
- Investigation of the role of mismatch repair enzymes in GAA repeats expansion |
[39] |
- In vitro study of FXN dynamic change in expression during differentiation |
[47] |
- Reversing transcriptional repression caused by elongated GAA tracks by altering specific epigenetic modifications |
[45] |
- Studies on DNA replication at the FXN locus |
[44] |
|
FRDA iPSC-derived cardiomyocytes |
- Generation of patient specific cells affected in FRDA |
[46] |
- Investigation of mitochondrial damage in FRDA |
[48] |
- Modeling iron-overload induced cardiomyopathy |
[49] |
- Drug screening platform for studying iron-overload cardiomyopathy in FRDA |
[50] |
- Cardiac-specific electrophysiological profile of FRDA |
[51] |
- Activating FXN expression by synthetic transcription elongation factors |
[52] |
|
FRDA iPSC-derived peripheral sensory neurons |
- Generation of patient specific cells affected in FRDA |
[46] |
- In vitro study of FXN dynamic change in expression |
[47] |
- Reversing oxidative stress and loss of Fe-S proteins with 2-Aminobenzamide HDAC inhibitors |
[53] |
|
FRDA iPSC-derived neural stem cells |
- Investigation of the role of mismatch repair enzymes in GAA repeats expansion |
[39] |
- Proteomic study of targets and pathways of 2-Aminobenzamide HDAC inhibitors |
[54] |
|
FRDA iPSC - derived neurons |
- Investigation of mitochondrial damage in FRDA |
[48] |
- Studying mechanism of apoptosis in FRDA |
[55] |
- FXN expression upregulation via zinc finger nuclease-mediated GAA tract excision |
[56] |
- FXN expression upregulation via 2-Aminobenzamide HDAC inhibitors |
[57] |
- FXN deficiency alleviation via HDACi treatment |
[58] |
- Activating FXN expression by synthetic transcription elongation factors |
[52] |
- FXN expression upregulation via 2-Aminobenzamide HDAC inhibitors
|
[59] |
|
FRDA iPSC-derived neural progenitors |
- Functional characterization and brain integration |
[60] |
|
FRDA iPSC-derived retinal pigment epithelium cells |
- Function and characterization of retinal pigment epithelium in FRDA patients |
[61] |